Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  azacitidine
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 173 for your search:
Start Over
Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AZA-MDS-001, NCT01201811
Phase II/III Chemotherapy with DNM/ARA-C Induction and DNM/ARA-C/TG, DNM/AZC, and ARA-C/TG Maintenance for Acute Myelogenous Leukemia
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: under 60
Sponsor:
Protocol IDs: NCI-D81-018-590, DFCI-80035
Phase II/III Combination Chemotherapy with AMSA/AZC or AMSA/VP-16 for Acute Nonlymphocytic Leukemia Refractory to Standard Therapy
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: NCI-D82-013-686
Phase II/III Consolidation Chemotherapy with VP-16/AMSA/AZC Following Induction with DNM/ARA-C/TG for Adult Primary or Secondary Leukemia
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: NCI-D82-051-605
Phase II/III Randomized Comparison of VP-16/AMSA vs VP-16/AMSA/AZC in Children with Refractory ANLL (Summary Last Modified 10/91)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 21 and under
Sponsor: NCI
Protocol IDs: POG-8820
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Phase: Phase III, Phase II
Type: Tissue collection/Repository, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-00242, SWOG-S1117, CDR0000723909, S1117, U10CA180888, U10CA032102, NCT01522976
Phase I/III Induction with ADR/ARA-C/VCR/PRDL and Consolidation and Maintenance with ADR/ARA-C, ADR/AZC, MePRDL/VCR/6-MP/MTX, or ARA-C for ANLL
Phase: Phase III, Phase I
Type: Treatment
Status: Closed
Age: under 50
Sponsor:
Protocol IDs: DFCI-76006, DFCI-VAPA-10
Phase III Randomized Study of Subcutaneous Azacytidine vs Observation in Myelodysplastic Syndrome
Phase: Phase III
Type: Treatment
Status: Closed
Age: over 15
Sponsor: NCI
Protocol IDs: CLB-9221, CALGB-9221
Phase III Therapy with DNM, ARA-C, AZC, Beta-TGDR, TG & BCG for Induction, Consolidation & Maintenance of Acute Myelogenous Leukemia (Summary Last Modified 04/97)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 15 and over
Sponsor:
Protocol IDs: SEG-77AML318, SEG-77AML0103
Chemotherapy with TAD (6-TG/ARA-C/DNM), ADR, AZC plus Immunotherapy with C. parvum, Allogeneic Leukemic Blasts for Acute Myelogenous Leukemia
Phase: Phase III
Type: Treatment
Status: Closed
Age: 3 and over
Sponsor:
Protocol IDs: UCLA-ALP-3
Phase III Study of Dzapo Chemotherapy Plus TG/AZC/ARA-C/VCR with or without Immunotherapy for Acute Myelogenous Leukemia in Children
Phase: Phase III
Type: Treatment
Status: Closed
Age: under 20
Sponsor: NCI
Protocol IDs: CCG-241
Phase III Comparison of ARA-C/DNM/TG vs ARA-C/VCR/DM for Remission Induction plus Intensive Multi-Drug Maintenance for Previously Untreated Pediatric ANLL
Phase: Phase III
Type: Treatment
Status: Completed
Age: 21 and under
Sponsor: NCI
Protocol IDs: POG-8101, POG-ANLL-2
Phase III Induction plus Early and Late Intensification Chemotherapy for Previously Untreated AML
Phase: Phase III
Type: Treatment
Status: Closed
Age: under 21
Sponsor:
Protocol IDs: NCI-D81-011-693, HOG-8130
Phase III Combination Chemotherapy (Cyclic vs Continuous) vs Bone Marrow Transplantation in Previously Untreated Pediatric ALL
Phase: Phase III
Type: Treatment
Status: Completed
Age: 21 and under
Sponsor: NCI
Protocol IDs: CCG-251
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AZA PH GL 2003 CL 001, NCT00071799
Start Over